Andrew Huberman Supplement Protocol — Complete Guide with Evidence Ratings

Why Huberman takes it: Brain and mood support; cardiovascular health — Huberman Lab podcast

What the evidence says: Meta-analysis supports a modest antidepressant effect of EPA-predominant omega-3 (Liao 2019, 26 RCTs), but Kelaiditis 2023 found effects on anxiety/depression inconsistent. For general brain health in replete people, and for cardiovascular prevention, large trials (VITAL) are largely null. The effect is real but narrow.

Why Huberman takes it: Hormone and immune support; correct deficiency — Huberman Lab podcast

What the evidence says: Best evidence is for correcting deficiency: Martineau's IPD meta-analyses (2017 BMJ; 2019 HTA) show supplementation modestly reduces acute respiratory infections, concentrated in deficient individuals. No good evidence that dosing already-replete men raises testosterone, or that high-dose prevents CVD/cancer (VITAL null).

Why Huberman takes it: Brain bioenergetics for focus plus muscle/strength — Huberman Lab podcast

What the evidence says: Among the most robustly supported: Desai 2024 meta-analysis shows ~1.1 kg greater lean mass with resistance training (grade A for muscle). Cognitive benefits are real but smaller (Prokopidis 2023; Xu 2024), strongest under sleep deprivation or in older adults (grade B for cognition). One of the highest-evidence items.

Why Huberman takes it: Brain-penetrant magnesium for sleep and cognition — Huberman Lab (sleep toolkit)

What the evidence says: Human data rest almost entirely on one small industry-funded RCT (Liu 2016, n=44) showing modest cognitive improvement in older adults; no robust trial shows threonate specifically improves sleep. Magnesium generally has better support for select outcomes, but the premium brain-penetrant marketing outruns its evidence.

Why Huberman takes it: Calm and relaxation without sedation — Huberman Lab (sleep toolkit)

What the evidence says: Multiple small RCTs support acute anxiolytic/calming effects without sedation (Hidese 2019; White 2016), and a systematic review (Williams 2020) concurs for stress and anxiety, though effects are modest and largely acute. Reasonable as a calm-focus aid and sleep-onset adjunct.

Why Huberman takes it: Chamomile flavonoid; GABAergic sleep aid — Huberman Lab (sleep toolkit)

What the evidence says: Essentially no human RCT tests isolated apigenin for sleep; the evidence is preclinical, with Kramer 2024 reviewing effects demonstrated in mice. Human support is indirect, extrapolated from chamomile. Unproven in humans.

Why Huberman takes it: Lowers core body temperature to speed sleep onset — Huberman Lab (sleep toolkit)

What the evidence says: Two small crossover studies from a single group (Bannai 2012) report ~3 g glycine before bed improves subjective sleep and next-day performance in sleep-restricted people. Independent replication is lacking and samples are tiny. Plausible but weak.

Why Huberman takes it: Serotonergic support to return to sleep after waking — Huberman Lab (sleep toolkit)

What the evidence says: Inositol has RCT support for panic/anxiety (Palatnik 2001) but only at ~18 g/day, roughly 20x Huberman's 900 mg. No credible RCT shows 900 mg improves sleep, so the sleep rationale is unproven and the anxiolytic dose is far higher than used here.

Why Huberman takes it: Acetylcholine precursor for acute focus and power — Huberman Lab podcast

What the evidence says: Human evidence is limited and concentrated in older/impaired populations (Traini 2013); ergogenic claims in healthy adults rest on a few very small acute studies. Some observational data raise a possible stroke-risk association at high chronic intake, warranting caution.

Why Huberman takes it: Dopamine/noradrenaline precursor for focus under demand — Huberman Lab podcast

What the evidence says: Jongkees 2015 review concludes tyrosine can help cognition specifically under acute stressors (sleep deprivation, cold, high load) but not at baseline in rested people, and results are inconsistent. A situational tool rather than a reliable daily nootropic.

Why Huberman takes it: Raise free testosterone, libido and drive — Huberman Lab (hormone episodes)

What the evidence says: Small RCTs and a review (Leitao 2021; Thu 2017) suggest it can modestly raise free testosterone and improve libido, mainly in hypogonadal or stressed men; effects in healthy young men are less certain and trials are small. Among the better-supported natural testosterone options, but still grade C.

Why Huberman takes it: Purported LH-mimetic to raise testosterone — Huberman Lab (hormone episodes)

What the evidence says: There is essentially NO human data; testosterone claims come entirely from rat studies (Yakubu 2005). Critically, Yakubu 2008 documented testicular toxicity at higher doses in rats, a safety signal with no human safety characterization. Unproven and a genuine safety concern.

Why Huberman takes it: Adaptogen; blunts fatigue and perceived effort — Huberman Lab podcast

What the evidence says: Small RCTs of extract SHR-5 (Darbinyan 2000; Olsson 2009) report reduced fatigue and improved performance, but trials are small, often industry-linked, and outcomes largely subjective. A reasonable anti-fatigue adaptogen with modest, low-certainty evidence.

Why Huberman takes it: Lowers cortisol/stress and supports sleep — Huberman Lab (stress/sleep episodes)

What the evidence says: The best-supported adaptogen here: meta-analyses (Akhgarjand 2022; Arumugam 2024) show significant reductions in perceived stress, anxiety and cortisol, and RCT/meta data support sleep (Langade 2020). Caveats: high heterogeneity, mostly small industry-linked trials, and rare liver-injury reports, so cycling is advised.

Why Huberman takes it: NAD+ precursor for cellular energy and longevity — Huberman Lab (longevity episodes)

What the evidence says: Human RCTs show NMN reliably raises NAD+ and produced isolated functional signals (Yoshino 2021; Yi 2022), but no human trial demonstrates slowed aging or extended lifespan. A promising but unproven longevity bet.